• linkedin
  • Increase Font
  • Sharebar

    Gene-based treatment provides sustained AMD therapy

    First-in-human trial explores anti-angiogenic subretinal viral vector

    Portland, OR—A novel gene-based therapy shows promise as being safe and well tolerated—with signs of clinical benefit in patients with advanced neovascular age-related macular degeneration (AMD), said Andreas K. Lauer, MD.

    Such findings are from the results of a dose-escalating phase I study investigating subretinal administration of a lentiviral vector expressing endostatin and angiostatin (RetinoStat, Oxford BioMedica).

    Recent: How has ophthalmology changed in 2016?

    In addition, assays of aqueous humor obtained through anterior chamber taps showed the treatment resulted in dose-dependent, significant, and persistent increases in expression of the endostatin and angiostatin genes.

    “The phase I study of RetinoStat is the first clinical trial in ophthalmology investigating lentiviral gene therapy, and this construct offers a distinct advantage for the treatment of wet AMD as it has the potential for a much longer duration of effect than current therapies,” said Dr. Lauer, Kenneth C. Swan Professor of Ophthalmology and chief, Vitreoretinal Division, Casey Eye Institute, Oregon Health and Science University, Portland, OR.

    Recent: LHON therapy: Excellent safety and potential visual benefits

    “The phase I study is also the first time therapeutic gene expression has been directly measured in an ophthalmology clinical trial,” Dr. Lauer said. “Notably, persistence of gene expression is being maintained during long-term follow-up that so far extends beyond 4 years.”

    More about the study

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';